Research programme: biosimilars - Momenta PharmaceuticalsAlternative Names: M 710; M-511
Latest Information Update: 21 Oct 2016
At a glance
- Originator Momenta Pharmaceuticals
- Developer Momenta Pharmaceuticals; Mylan
- Class Biological factors; Monoclonal antibodies; Proteins
- Mechanism of Action CD80 antigen inhibitors; Immunosuppressants; T cell activation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
- Research Cancer